ZIOPHARM Commences Randomized Phase II Study of Palifosfamide in Soft Tissue Sarcoma

09-Sep-2008 - USA

ZIOPHARM Oncology, Inc., announced that the first patient has been dosed in its international Phase II randomized controlled trial of palifosfamide (ZIO-201) in patients with soft-tissue sarcoma (STS): This is a Phase II multi-center, parallel group, randomized study of palIfosfamide plus doxorubicin versus doxorubiCin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO). Approximately 100 evaluable subjects are expected to be enrolled in this multi-center trial, which is being conducted at sites in the U.S. and Europe by several key opinion leaders in sarcoma.

This Phase II trial will evaluate the clinical benefit of palifosfamide administered with doxorubicin compared with single-agent doxorubicin in subjects diagnosed with unresectable or metastatic STS in the front- or second-line treatment setting. The primary endpoint is assessment of the difference in progression-free survival between subjects in the two arms of the trial.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances